Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 12, 2020

SELL
$15.87 - $23.12 $379,388 - $552,706
-23,906 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$16.91 - $36.27 $533,375 - $1.14 Million
-31,542 Reduced 56.89%
23,906 $435,000
Q2 2019

Aug 12, 2019

BUY
$31.0 - $36.3 $366,048 - $428,630
11,808 Added 27.06%
55,448 $1.97 Million
Q1 2019

May 08, 2019

BUY
$31.58 - $46.35 $6,284 - $9,223
199 Added 0.46%
43,640 $1.47 Million
Q4 2018

Feb 13, 2019

SELL
$30.43 - $56.65 $700,468 - $1.3 Million
-23,019 Reduced 34.64%
43,441 $1.43 Million
Q3 2018

Nov 13, 2018

BUY
$46.46 - $68.49 $839,857 - $1.24 Million
18,077 Added 37.36%
66,460 $4.05 Million
Q2 2018

Aug 09, 2018

BUY
$46.25 - $104.45 $2.24 Million - $5.05 Million
48,383 New
48,383 $2.36 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track British Columbia Investment Management Corp Portfolio

Follow British Columbia Investment Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.